2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow Chronic Lymphoid Leukemia: new trials by email Literature Review of Chronic Lymphoid Leukemia trials Research Report on Chronic Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Zanubrutinib - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | German CLL Study Group | 42 | 2020-10-01 | 2026-08-20 |
| Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Venetoclax - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | French Innovative Leukemia Organisation | 82 | 2019-05-22 | 2025-11-26 |
Leukemia, B-Cell (2)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
venetoclax (2) · Bendamustine Hydrochloride (1) · obinutuzumab (1) · zanubrutinib (1)
French Innovative Leukemia Organisation (1) · German CLL Study Group (1)
France (1) · Germany (1)
2018 (1)